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Soy foods have had an important dietary role in Asian countries for centuries, and in recent years they 
have become increasingly popular in Western countries as a result of their suggested health benefits. 
Nevertheless, there are some concerns that soy can have a negative effect on thyroid function and 
can alter the levels of thyroid hormones. The aim of this systematic review was to investigate the 
link between soy or soy product consumption and thyroid function via the measurement of thyroid 
hormone levels. A systematic review and meta-analysis was undertaken on all randomised controlled 
trials of studies including soy as an intervention and where free triiodothyronine (fT3), free thyroxine 
(fT4) and thyroid stimulating hormone (TSH) was measured. The search included PubMed, MEDLINE, 
EMBASE, Cochrane and sources for the grey literature. Quantitative data synthesis was performed 
using a random-effects model, with standardized mean difference (SMD) and 95% confidence interval 
as summary statistics. A total of 18 articles were suitable for review. The meta-analysis showed no 
significant changes in fT3 (WMD: 0.027 pmol/L, 95% CI: −0.052, 0.107, p = 0.499; I2: 55.58%), fT4 
(WMD: −0.003 pmol/L, 95% CI: −0.018, 0.011, p = 0.656; I2: 87.58%) while an elevation in TSH 
levels was observed (WMD: 0.248 mIU/L, 95% CI: 0.001, 0.494, p = 0.049; I2: 80.31%) levels with soy 
supplementation. There was no evidence of publication bias. Soy supplementation has no effect on the 
thyroid hormones and only very modestly raises TSH levels, the clinical significance, if any, of the rise in 
TSH is unclear.
Soy has been a staple in the diet in South and East Asian countries for many years and has become popular in 
Western countries as a result of the suggested health benefits that include protection against osteoporosis1, cardi-
ovascular diseases2, diabetes3,4, breast cancer5 and prostate cancer6.
The two main components of soy thought to be responsible for the proposed health benefits are soy protein 
and the soy isoflavones. It is believed that isoflavones present in soy are the main active compounds that produce 
both hormonal and non-hormonal effects7. Isoflavones are a subclass of common plant compounds called flavo-
noids. They usually exist in food as biological inactive forms, such as genistin and daizin, which are present in 
soy as β-D-glycosides. These glycosides can be hydrolyzed and deconjugated by β-glycosidases synthesized by 
intestinal bacteria to form biologically active aglycone forms of isoflavones, such as genistein and daidzein. Public 
interest in the health benefits of soy isoflavones has led to the development of isoflavone supplements and the 
fortification of foods with isoflavones7,8.
However, there is speculation that for certain subsets of the population soy foods and isoflavones may be det-
rimental. Concern has been expressed that soy may adversely affect thyroid function in susceptible individuals by 
interfering with the absorption of synthetic thyroid hormone9,10. Although the anti-thyroid effect of soy has been 
investigated in animals for decades11, the identification of several cases of thyroid enlargement in infants con-
suming soy formula in the early 1960s, over 60 years ago, became apparent12. It has been shown that isoflavones 
inhibit the activity of thyroid peroxidase (TPO), an enzyme involved in the synthesis of triiodothyronine (T3) and 
thyroxine (T4), in vivo in rats13 and in vitro14.
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There is some evidence to suggest that soy consumption is associated with thyroid disorders such as hypo-
thyroidism, goitre, and autoimmune thyroid disease9. The potential public health implications of the possible 
anti-thyroid effects of soy is important since as many as 10% of postmenopausal women, for whom soy foods have 
particular appeal, may be hypothyroid, and a large proportion of these may be undiagnosed15. Thus, it is crucial 
to clarify the relationship between soy and thyroid function. There was a review of literature on the effect of soy 
protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients in 2006, although 
this was not a prospectively registered systematic review16. In 2015, the European Food Safety Authority (EFSA) 
conducted a risk assessment that included the effect of soy protein and soy isoflavones on thyroid function17, 
however, there have been a number of randomised controlled studies published after this review18–20. The EFSA 
concluded soy isoflavones were without effect on thyroid function.
Material and Methods
search strategy. A comprehensive, systematic search for information was conducted in several academic 
databases as well as in sources of grey literature based on following the main search string:
((TSH OR thyrotropin OR triiodothyronine OR thyroxine OR “Iodide peroxidase” OR “TPO protein” OR 
“TPO proteins” OR thyroid* OR T4 OR T3) OR hypothyroid* OR levothyroxine) AND (equol OR phytoes-
trogen*OR genestein OR genistein OR daidzein OR glycitein OR soy* OR genistin OR “lipofundin s” OR 
“sodium-iodide symporter” OR GCP OR isoflavones).
Pre-searches to identify relevant search terms, search strategies and information sources were conducted in 
May–June 2016, and the main search was carried out in July–August 2016. Additional searches for grey literature 
was later conducted during August- September 2016.
PubMed was used to systematically develop and test the search string, which later was adapted and applied to 
MEDLINE (WOS), EMBASE (OVID), and Cochrane.
All terms were searched in the fields “Abstract” and “Article Title” and in MeSH/Subject Headings/Thesaurus 
when available. No filters or limitations were applied in order to retrieve the best possible result and to avoid 
excluding pre- indexed materials.
All references were uploaded to the reference management software EndNote and transferred to the system-
atic review software Covidence for de-duplication, screening and data extraction.
In addition to the search in academic databases, ProQuest Dissertation and Thesis, Ethos, Open Grey, The 
New York Academy of Grey Literature Reports and Clinical Trials were searched for grey materials. The sources 
were selected based on pre-searches and includes American, European as well as global publications. Due to the 
lack of advanced search features in many of the grey resources, broader search strings than the one used in the 
academic databases had to be applied.
Figure 1. PRISMA Studies Selection Flow Diagram. *In addition to the main search and screening process 
documented in the PRISMA flow diagram, an updated search in PubMed was conducted before publishing. 145 
new references were identified and screened by hand. 3 additional papers were selected to be added to the study 
leading to a result of 18 papers included in the meta- analysis.
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An updated search in PubMed with a publication filter for the period August 2016–August 2018 was addition-
ally conducted in August 2018 to include the most recent papers published.
study selection. Original studies were included if they met the following inclusion criteria: (i) Adult trials, 
(ii) being a randomized controlled trial with either parallel or cross-over design, (iii) investigating the impact 
of soy products e.g. isoflavones, genistein and/or daizein on plasma/serum concentrations of TSH, fT3 and fT4, 
and, (iv) presentation of sufficient information on TSH, fT3 and fT4 concentrations at baseline and at the end of 
follow-up in each group or providing the net change values. Exclusion criteria were: (i) Animal trials, (ii) Child/
Figure 2. Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of soy 
products on fT3, fT4 and TSH levels.
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Adolescent Trials (iii) observational studies with case-control, cross-sectional or cohort design, and (iv) lack of 
sufficient information on baseline or follow-up TSH, fT3 and fT4 concentrations.
Data extraction. Eligible studies were reviewed and the following data were abstracted by two co-authors. 
Any disagreements were resolved through discussion and consultation with a third co-author: (1) first author’s 
name; (2) year of publication; (3) country were the study was performed; (4) study design; (5) number of partici-
pants in the intervention and control/placebo groups; (6) intervention assigned to the control group if any; (7) soy 
product type (isoflavones, genistein and/or daidzein) and dose of soy supplement; (8) treatment duration; (9) age, 
gender and body mass index (BMI) of study participants; and (9) data regarding baseline and follow-up plasma 
concentrations of TSH, fT3 and fT4.
Quantitative Data Synthesis. Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) 
V2 software (Borenstein M et al. Comprehensive Meta-analysis Version 2, Biostat, Englewood NJ, 2005). A 
random-effects model (using DerSimonian-Laird method) and the generic inverse variance weighting method 
were used to compensate for the heterogeneity of studies in terms of study design, treatment duration, and 
the characteristics of populations being studied21. Standard deviations (SDs) of the mean difference were cal-
culated using the following formula: SD = square root [(SDpre-treatment)2 + (SDpost-treatment)2 − (2 R × SDpre-treatment 
× SDpost-treatment)], assuming a correlation coefficient (R) = 0.5. Where standard error of the mean (SEM) was only 
Figure 3. Leave-one-out sensitivity analysis of the impact of soy products on fT3, fT4 and TSH levels.
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reported, standard deviation (SD) was estimated using the following formula: SD = SEM × sqrt (n), where n is the 
number of subjects. All fT3, fT4 and TSH values were collated in pmol/L, pmol/L and mIU/L, respectively. Effect 
sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). In case of studies 
with multiple treatment arms and a single control group, the number of subjects in the control group was divided 
into equal parts to avoid double counting of a single individual in the meta-analysis. In order to evaluate the influ-
ence of each study on the overall effect size, a sensitivity analysis was conducted using the leave-one-out method 
(i.e., removing one study each time and repeating the analysis. Since pre-test-post-test correlation coefficients 
(R) were not reported by the studies, an (R)value of 0.5 was assumed through this meta-analysis, as this value is a 
conservative estimate for R which ranges between 0 and 1. In order to check if the R value can alter the results of 
meta-analysis, sensitivity analyses were performed by repeating the analysis with R values of 0.2, 0.3, 0.7 and 0.8. 
The results showed the robustness of the pooled estimate with different R values.
publication bias. Evaluation of funnel plot, Begg’s rank correlation and Egger’s weighted regression tests 
were employed to assess the presence of publication bias in the meta-analysis. When there was evidence of fun-
nel plot asymmetry, potentially missing studies were imputed using the “trim and fill” method22. This method 
imputes the potentially missing studies on either side of the funnel plot, and then re-computes the effect size 
considering inclusion of potentially missing studies22.
Results
4925 references were found through the literature search, with 1816 references remaining after de-duplication. 
Additionally, 145 papers were identified in the updated PubMed search and hand screened. A total of 4 new 
papers were selected to be included in the study. A full search log, including search string, results and notes can 
be found in Appendix 1.
In total, after the initial and updated searches, 84 references were identified in the TI/AB screening, 23 were 
remaining after full text screening and a final of 18 selected to be included in the meta-analysis. A PRISMA flow 
diagram of the screening and selection process can be found in Fig. 1.
The interventions used in the studies were mainly food supplements containing soy isoflavones, soy extract, 
soy protein, daidzein-rich isoflavones and genistein alone. The doses used in the studies ranged from 40–200 mg/
day. In comparison, in one survey based study older Japanese adults consumes approximately 25–50 mg of iso-
flavones (expressed as aglycone equivalents) per day23. We included only fT3 and fT4 since they are the metabol-
ically active form of thyroid hormones since they are not bound to plasma proteins including thyroid binding 
globulin.
Since the primary endpoints in most studies included were not related to thyroid function except seven stud-
ies19,20,24–28, the sample sizes were mainly determined on the basis of expected changes in other endpoints. Data 
from 18 studies were included in the meta-analysis3,18–20,24–37. Out of this, two studies included both men and 
women19,20, 3 studies included men only25,29,36, whilst the other studies included only women. Two studies looked 
into changes in thyroid function in patients with subclinical hypothyroidism19,20.
Quantitative data synthesis. Meta-analysis of data from 21 and 22 treatment arms did not reveal any 
significant effect of soy product consumption on fT3 (WMD: 0.027 pmol/L, 95% CI: −0.052, 0.107, p = 0.499; 
I2: 55.58%) and fT4 (WMD: −0.003 pmol/L, 95% CI: −0.018, 0.011, p = 0.656; I2: 87.58%). However, analysis 
of 26 treatment arms revealed a significant elevation in TSH levels following soy product consumption (WMD: 
0.248 mIU/L, 95% CI: 0.001, 0.494, p = 0.049; I2: 80.31%) (Fig. 2). Iterative removal of included study arms from 
the meta-analysis did not reveal sensitivity of the pooled effect size estimate to any single treatment arm in the 
meta-analyses of fT3 and fT4. However, the meta-analysis of TSH was sensitive to one of the included treatment 
arms (Fig. 3).
We have performed subgroup analysis of TSH for potential confounding factors and sources of heterogeneity 
between studies which included gender, menopause status, health status at baseline, treatment duration and pres-
ence of subclinical hypothyroidism at baseline (Table 1).
WMD (95% CI) p-Value Between group p-value
Gender
Male 0.004 (−0.191, 0.199) 0.968
0.004
Female 0.232 (−0.087, 0.552) 0.154
Menopausal status
Premenopausal 0.020 (−0.565, 0.606) 0.946
0.580
Postmenopausal 0.184 (−0.098, 0.466) 0.201
Health status at baseline
Healthy 0.131 (−0.108, 0.371) 0.282
0.121
Not healthy 0.493 (0.104, 0.883) 0.013
Treatment duration
<3 months 0.006 (−0.180, 0.191) 0.952
0.710
>3 months 0.319 (0.034, 0.604) 0.028
Subclinical hypothyroidism at baseline
Yes 0.692 (0.333, 1.052) <0.001
0.032
No 0.199 (−0.074, 0.472) 0.154
Table 1. Subgroup analysis for changes in TSH.
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Subgroup analysis of changes in TSH reveals treatment duration of more than or equal to three months (WMD 
(95% CI) 0.319 (0.034, 0.604; p value 0.028) and presence of subclinical hypothyroidism at baseline (WMD (95% 
CI) 0.692 (0.333, 1.052; p value < 0.001) were significant.
publication bias. Visual inspection of Begg’s funnel plots revealed asymmetry in the meta-analyses of soy 
product’s effects on fT3, fT4 and TSH levels. Using trim and fill correction, 3, 2 and 6 potentially missing studies 
were imputed (Fig. 4). Imputed effect sizes and the results of Begg’s rank correlation and Egger’s regression tests 
are summarized in Table 2.
Figure 4. Funnel plot detailing publication bias in the studies reporting the impact of soy products on fT3, fT4 
and TSH levels.
na WMD 95% CI P-valueb P-valuec
fT3 3 0.068 −0.012, 0.148 0.381 0.374
fT4 2 −0.003 −0.018, 0.011 0.338 0.224
TSH 6 0.358 0.139, 0.577 0.067 0.065
Table 2. Imputed effect sizes and the results of Begg’s rank correlation and Egger’s regression tests for the meta-
analysis of Soy’s effects on thyroid hormones. aThe number of imputed studies according to the trim and fill 
correction method; bBegg’s rank correlation test; cEgger’s weighted regression test.
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Discussion
This systematic review showed that there was a significant change in TSH as a result of soy protein and/or isofla-
vones supplementation though with no significant changes in fT3 and fT4 levels suggesting that whilst soy can 
adversely affect thyroid function, clinically this may not be significant. This is the converse reported from the 
EFSA risk assessment on 2015 that did not show that food supplements containing isolated isoflavones caused 
any significant effects on thyroid function in peri- or post-menopausal women17; however, new randomised con-
trolled trials have been published since this report.
A study that examined the effect of soy isoflavones in patients with type 2 diabetes and hypogonadism showed 
a significant increase in TSH and reduction in fT4 with 12 weeks of combined soy protein and isoflavone sup-
plementation, though none developed subclinical or overt hypothyroidisim36. Another study published recently 
comparing soy protein and casein protein without soy isoflavones in patients with subclinical hypothyroidism 
reported no significant changes in thyroid function19.
In one of the studies in patients with subclinical hypothyroidism comparing the effect of low dose phytoestro-
gen (2 mg comparable to Western diet) with higher dose phytoesterogen (comparable to a vegetarian diet), there 
were no significant changes in thyroid function test as a group. However, of the 60 patients, six of the 52 female 
subjects (11.5%) progressed into overt hypothyroidism after the 16-mg isoflavone arm of the 6-month period 
showing a 3-fold increase (standardized rate ratio of 3.6 (95% confidence interval = 1.9, 6.2)) in progression from 
subclinical to overt hypothyroidism20.
Soy containing food products have been potentially implicated in deterioration of thyroid function. Goitre has 
been seen in infants fed soy formula; this is usually reversed by changing to cows’ milk or iodine-supplemented 
diets12,38. In vitro research14,39 and studies in rodents13,40 supplemented with isolated isoflavones suggests that soy 
can have an anti-thyroid effect. There are concerns that they may compromise thyroid function14,41, an issue for 
patients with subclinical or overt hypothyroidism, particularly during pregnancy42–44.
In vitro studies have demonstrated that isoflavones inhibit thyroid peroxidase (TPO), an enzyme involved in 
the synthesis of T3 and T414.
Subgroup analysis of changes in TSH reveals treatment duration of more than or equal to three months and 
presence of subclinical hypothyroidism at baseline were significant. This suggests that soy could have more effect 
on people with compromised thyroid function at baseline or having various disease states or taken for a longer 
duration.
Limitations of the present meta-analysis include the fact that the pooled population analysed in this 
meta-analysis included a limited number of subjects because the sample size in some of the clinical trials was 
small, and the treatment duration of many of the trials was short. Most of the studies which showed significant 
rise in TSH and improvement in cardiovascular risk markers were conducted by the group at Hull, UK who has 
performed this meta-analysis18–20,36 but they have done most studies in patients with diseased states such as type 
2 diabetes and also in patients with partly compromised thyroid function such as subclinical hypothyroidism at 
baseline18–20,36. There was only a modest 10% increase in TSH which may not be relevant in healthy population 
but could have a clinically significant effect of patients with compromised thyroid function such as subclinical 
hypothyroidism. Based on this, further research and analysis is recommended including further investigation 
involving subclinical hypothyroid patients, not only because of the possible effects on thyroid function but due to 
potential multiple beneficial effects including cardiovascular health, metabolic syndrome, diabetes, bone health 
and post-menopausal symptoms19,45.
In conclusion, this meta-analysis suggests that soy supplementation has no effect on the thyroid hormones and 
modestly raises TSH levels, the clinical significance, if any, of the rise in TSH is unclear.
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